Patients with indolent non-Hodgkin lymphoma (iNHL) refractory to current standard of care ‘mAbs’ therapies may get augmented responses with a novel cytokine IL15 immunotherapy, early studies in humans suggest. In phase I trial findings presented at the American Association of Cancer Research 2018 annual meeting in Chicago, researchers from the Washington University School of Medicine ...
AACR 2018: Novel immunotherapy shows promise in refractory non-Hodgkin lymphoma
By Michael Woodhead
18 Apr 2018